scholarly journals Clinical Experience with Generic Rasagiline (Ralago<sup>&reg;</sup>) in Patients with Parkinson’s Disease: An Open-Label, Multicenter, Observational Study

2019 ◽  
Vol 08 (02) ◽  
pp. 18-34 ◽  
Author(s):  
Dávid Pintér ◽  
Júlia Lajtos ◽  
József Janszky ◽  
Norbert Kovács
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Observational Study ◽  
Clinical Experience ◽  
Open Label ◽  
Multicenter Observational Study

Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience

2017 ◽  
Vol 375 ◽  
pp. 186-189 ◽  
Author(s):  
Haruo Nishijima ◽  
Tatsuya Ueno ◽  
Tomoya Kon ◽  
Rie Haga ◽  
Yukihisa Funamizu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Experience ◽  
Open Label ◽  
Mood Symptoms

scholarly journals Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Elisabetta Tronci ◽  
Camino Fidalgo ◽  
Manolo Carta
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cell Transplantation ◽  
Open Label ◽  
Double Blind ◽  
Clinical Investigations ◽  
Serotonin Neurons ◽  
Ventral Mesencephalic ◽  
Preclinical And Clinical Studies ◽  
Foetal Cell

Transplantation of dopamine- (DA-) rich foetal ventral mesencephalic cells emerged as a promising therapy for Parkinson’s disease (PD), as it allowed significant improvement of motor symptoms in several PD patients in open-label studies. However, double-blind clinical trials have been largely disappointing. The general agreement in the field is that the lack of standardization of tissue collection and preparation, together with the absence of postsurgical immunosuppression, played a key role in the failure of these studies. Moreover, a further complication that emerged in previous studies is the appearance of the so-called graft-induced dyskinesia (GID), in a subset of grafted patients, which resembles dyskinesia induced by L-DOPA but in the absence of medication. Preclinical evidence pointed to the serotonin neurons as possible players in the appearance of GID. In agreement, clinical investigations have shown that grafted tissue may contain a large number of serotonin neurons, in the order of half of the DA cells; moreover, the serotonin 5-HT1A receptor agonist buspirone has been found to produce significant dampening of GID in grafted patients. In this paper, we will review the recent preclinical and clinical studies focusing on cell transplantation for PD and on the mechanisms underlying GID.

The oasis (opicapone in sleep disorder) study in Parkinson's disease: Design and rationale of an open-label, single-arm, pilot trial

2021 ◽  
Vol 429 ◽  
pp. 119430
Author(s):  
Raquel Costa ◽  
Claudia Trenkwalder ◽  
Joaquim Ferreira ◽  
Diogo Magalhães ◽  
José Rocha ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Sleep Disorder ◽  
Pilot Trial ◽  
Open Label
Sign in / Sign up

Export Citation Format

Share Document